Godden C W, Campbell M J, Hussey M, Cogswell J J
Department of Paediatrics, Poole NHS Trust Hospital, Dorset.
Arch Dis Child. 1997 Feb;76(2):155-8. doi: 10.1136/adc.76.2.155.
To determine whether nebulised budesonide improves the symptoms or shortens the duration of stay of children admitted to hospital with a clinical diagnosis of croup.
A prospective, randomised, double blind placebo controlled trial. Patients received either nebulised budesonide or placebo every 12 hours. The main outcome measures were duration of inpatient stay and croup scores at 30 minutes, one, two, four, 12, and 24 hours.
87 patients (89 admissions) aged 7-116 months entered the trial. Nebulised budesonide was associated with a significant improvement in symptoms at 12 hours (95% confidence interval (CI) 1 to 3) and 24 hours (95% CI 0 to 3). Patients with an initial croup score above 3 demonstrated a significant improvement in symptoms at two hours (95% CI 1 to 3). Nebulised budesonide was also associated with a 33% reduction in the length of stay (95% CI 2% to 63%) when the confounding variables of age, initial croup score, and coryzal symptoms were taken into consideration.
Nebulised budesonide is an effective treatment for children admitted to hospital with a clinical diagnosis of croup.
确定雾化吸入布地奈德是否能改善临床诊断为哮吼的住院儿童的症状或缩短其住院时间。
一项前瞻性、随机、双盲、安慰剂对照试验。患者每12小时接受一次雾化吸入布地奈德或安慰剂。主要观察指标为住院时间以及在30分钟、1小时、2小时、4小时、12小时和24小时时的哮吼评分。
87名年龄在7至116个月的患者（89例入院）进入试验。雾化吸入布地奈德在12小时（95%置信区间（CI）1至3）和24小时（95%CI 0至3）时与症状显著改善相关。初始哮吼评分高于3分的患者在2小时时症状有显著改善（95%CI 1至3）。在考虑年龄、初始哮吼评分和鼻卡他症状等混杂变量时，雾化吸入布地奈德还与住院时间缩短33%相关（95%CI 2%至63%）。
雾化吸入布地奈德是临床诊断为哮吼的住院儿童的一种有效治疗方法。
